Cluster 1 is primarily concerned with four research directions: 1etiology, which includes the connection between uterine leiomyoma and uLMS, as well as genetic and protein-level pathological mechanisms involving p53, p16, ALL, MED12, etc.; 2diagnosis and outcome, which includes prognostic factors and survival rates; 3clinical research advancements in the treatment of uLMS, with an emphasis on different chemotherapy regimens; and 4surgical approaches for uLMS, including laparoscopy, mastectomy, and morcellation. Here, MED12 is linked to uterine corpus leiomyoma.